Medscape (10/19, Davenport, Subscription Publication) reported, “Use of selective serotonin reuptake inhibitors (SSRIs) appears to amplify the living environment of patients with major depressive disorder (MDD) in a dose-dependent manner, so that those in more positive situations are more likely to achieve remission compared with their counterparts living in less favorable conditions,” research indicated. In arriving at that conclusion, investigators examined data from 4,000 adult patients from the STAR*D study. The findings were presented at the 31st European College of Neuropsychopharmacology Congress.
Related Links:
— Medscape (requires login and subscription)